Mode
Text Size
Log in / Sign up
N/A Completed N=227 Randomized Single-blind Treatment

Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not

Arthroplasty, Replacement, Hip · Blood Transfusion · Blood Transfusion, Autologous
Source: ClinicalTrials.gov NCT00822588 ↗
Enrolled (actual)
227
Serious AEs
6.5%
Results posted
May 2011
Primary outcomePrimary: Number of Participants in Need for Bank Blood Transfusion — 9; 13 Participants

Summary

The study is a prospective, controlled, randomised and assessor blind study that investigate if the need for bank blood transfusion could be reduced in patients, undergoing primary or revision total hip replacement surgery, who receive their own blood back with the medical device Sangvia. A comparison in need for bank blood will be made between patients that either receive their own blood back or not.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants in Need for Bank Blood Transfusion
9; 13 —

Eligibility Criteria

Inclusion Criteria

  • Provision of informed consent
  • Scheduled for primary or secondary, cemented or non-cemented, total hip arthroplasty
  • Classified as ASA Physical Status Classification System class P1, P2 or P3 according to the American Society of Anaesthesiology.

Exclusion Criteria

  • Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site)
  • Previous enrollment or randomisation of treatment in the present study
  • Expected or confirmed participation in another clinical study, that may interfere with the present study, during the study period
  • Suspected severe non-compliance to protocol as judged by the investigator
  • Current symptoms of haemophilia
  • Current symptoms of hyperkalaemia
  • Current symptoms of systemic infection or local infection in the operation field
  • Current symptoms of impaired renal function including creatinine/clearance levels above the normal reference values
  • History of or presence of malignant disease with propensity for systemic spread during the last 5 years
  • Current or expected use of cytotoxic drugs
  • Current untreated anaemia (e.g. sickle cell anaemia), i.e. Hb concentration < 11 g/dl (7 mmol/l)
  • Use of recombinant erythopoetin
  • Use of aprotinin and/or fibrin sealant
  • Use of other autologous blood transfusion than that with the Sangvia® system (e.g. CellSaver, pre-donation, acute normovolemic haemodilution etc.)
  • Women of childbearing age
  • Fractures
  • Revision/secondary total hip surgery with expected serious bone grafting
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00822588). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search